Long-term cardiovascular safety of COVID-19 vaccination according to brand, dose and combinations: Cohort study of 46 million adults in England
Ip, S. H. Y.; North, T.-L.; Torabi, F.; Li, Y.; Abbasizanjani, H.; Akbari, A.; Horne, E. M. F.; Denholm, R.; Keene, S.; Denaxas, S.; Banerjee, A.; Khunti, K.; Sudlow, C.; Whiteley, W.; Sterne, J. A. C.; Wood, A.; Walker, V.
Show abstract
Using longitudinal health records from 45.7 million adults in England followed for a year, our study compared the incidence of thrombotic and cardiovascular complications after first, second and booster doses of brands and combinations of COVID-19 vaccines used during the first two years of the UK vaccination program with the incidence before or without the corresponding vaccination. The incidence of common arterial thrombotic events (mainly acute myocardial infarction and ischaemic stroke) was generally lower after each vaccine dose, brand and combination. Similarly, the incidence of common venous thrombotic events, (mainly pulmonary embolism and lower limb deep venous thrombosis) was lower after vaccination. There was a higher incidence of previously reported rare harms after vaccination: vaccine-induced thrombotic thrombocytopenia after first ChAdOx1 vaccination, and myocarditis and pericarditis after first, second and transiently after booster mRNA vaccination (BNT-162b2 and mRNA-1273). These findings support the wide uptake of future COVID-19 vaccination programs.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Effectiveness of ChAdOx1-S COVID-19 Booster Vaccination against the Omicron and Delta variants in England 94%
- Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation: test negative case-control study 94%
- Waning of SARS-CoV-2 antibodies targeting the Spike protein in individuals post second dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and risk of breakthrough infections: analysis of the Virus Watch community cohort 94%
Similar papers in this journal
- Immune Memory Response After a Booster Injection of mRNA-1273 for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) 92%
- What level of neutralising antibody protects from COVID-19? 92%
- Immunogenicity and reactogenicity of a heterologous COVID-19 prime-boost vaccination compared with homologous vaccine regimens 92%
Similar papers in this journal
- Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: whole population cohort study in 46 million adults in England 97%
- Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy: a multi-database, self-controlled case series study 94%
- Outcome of COVID-19 in hospitalised immunocompromised patients: an analysis of the WHO ISARIC CCP-UK prospective cohort study 92%
Similar papers in this journal
- Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July – November 2021 93%
- Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death 92%
- Effectiveness and efficiency of immunisation strategies to prevent RSV among infants and older adults in Germany: a modelling study 92%
Similar papers in this journal
- Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors 92%
- Assessing Healthy Vaccinee Bias in COVID-19 Vaccine Effectiveness Studies: A National Cohort Study in Qatar 90%
- An agnostic study of associations between ABO and RhD blood group and phenome-wide disease risk 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.